Cargando…
Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
PURPOSE: To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED). METHOD: Treatment wa...
Autores principales: | Sundlöv, Anna, Sjögreen-Gleisner, Katarina, Svensson, Johanna, Ljungberg, Michael, Olsson, Tomas, Bernhardt, Peter, Tennvall, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506097/ https://www.ncbi.nlm.nih.gov/pubmed/28331954 http://dx.doi.org/10.1007/s00259-017-3678-4 |
Ejemplares similares
-
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients
por: Sundlöv, Anna, et al.
Publicado: (2022) -
Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy
por: Sundlöv, Anna, et al.
Publicado: (2018) -
SPECT image segmentation for estimation of tumour volume and activity concentration in (177)Lu-DOTATATE radionuclide therapy
por: Gustafsson, Johan, et al.
Publicado: (2017) -
Bone Marrow Absorbed Doses and Correlations with Hematologic Response During (177)Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
por: Hagmarker, Linn, et al.
Publicado: (2019) -
Optimizing the Schedule of PARP Inhibitors in Combination with (177)Lu-DOTATATE: A Dosimetry Rationale
por: Hallqvist, Andreas, et al.
Publicado: (2021)